CareLit · DOI-Nachweis · Das Gesundheitswesen
Multi-dimensional capture of patient-relevant endpoints in regulatory trials and health technology assessments in oncology two years after introduction of the German AMNOG health care reform
DOI 10.1055/s-0033-1354237
Bibliografische Angaben
Nachweis in CareLit
Autor:innenDintsios, C.; Knoerzer, D.; Dünne, A.; Schwartz, F.; Ruof, J.
ZeitschriftDas Gesundheitswesen
Ausgabe8/09/2013
Jahrgang / SeitenJg. 75 · S. 1 bis 1
Kernaussage aus der Literatur
Abstract-Vorschau
Objectives: With the introduction of AMNOG in January 2011, an early benefit assessment (EBA) was required for new medicines in Germany. EBAs are based on the additional therapeutic benefit of a drug on patient-relevant endpoints (PREs). We compared the acceptance of PREs for oncology in regulatory trials, and in EBAs conducted by German health technology assessment (HTA) bodies. Methods: EBAs on oncology drugs and…
Zitieren
Zitierempfehlung
Dintsios, C.; Knoerzer, D.; Dünne, A.; Schwartz, F.; Ruof, J (2013) Multi-dimensional capture of patient-relevant endpoints in regulatory trials and health technology assessments in oncology two years after introduction of the German AMNOG health care reform. Das Gesundheitswesen, 75 (8/09), 1 bis 1. https://doi.org/10.1055/s-0033-1354237
Mit CareLit weiterarbeiten